John Sweetenham, senior director of clinical affairs and executive medical director of Huntsman Cancer Institute at The University of Utah, in a recent write up takes a look at some of the potential benefits real-world evidence (RWE) has to offer in oncology, as well as some of the possible problems.
RWE, for instance, could play a key role in expediting the approval of new cancer treatments as the Food and Drug Administration (FDA) has floated using evidence generated in real-world settings instead of data from prospective studies.
While bringing big data into the mix “provides an exciting opportunity,” such large data sets could produce some issues.
“The real world in oncology is difficult to define, and varies depending on our practice setting, demographics and access to care, but there is no doubt that well-constructed real-world evidence — if used appropriately — could be a huge benefit to approval of new treatments for our patients,” Sweetenham writes.
To read Sweetenham’s full article on Healio, click here.